| Primary |
| Immunodeficiency Common Variable |
61.7% |
| Hypogammaglobulinaemia |
12.1% |
| Immunodeficiency |
7.4% |
| Hypoglobulinaemia |
3.4% |
| Primary Immunodeficiency Syndrome |
3.4% |
| Selective Igg Subclass Deficiency |
1.8% |
| Combined Immunodeficiency |
1.7% |
| Blood Immunoglobulin G Decreased |
1.5% |
| Congenital Hypogammaglobulinaemia |
1.4% |
| B-cell Lymphoma |
1.2% |
| Selective Iga Immunodeficiency |
1.1% |
| Bruton's Agammaglobulinaemia |
0.6% |
| Premedication |
0.6% |
| Alpha-1 Anti-trypsin Deficiency |
0.3% |
| Back Injury |
0.3% |
| Chronic Lymphocytic Leukaemia |
0.3% |
| Humoral Immune Defect |
0.3% |
| Prophylaxis |
0.3% |
| Asthma |
0.2% |
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
0.2% |
|
| Respiratory Tract Infection |
12.7% |
| Sinusitis |
11.0% |
| Pneumonia |
8.7% |
| Upper Respiratory Tract Infection |
8.7% |
| Urinary Tract Infection |
7.3% |
| Fatigue |
6.7% |
| Headache |
5.3% |
| Infusion Site Erythema |
4.0% |
| Pain |
4.0% |
| Diarrhoea |
3.3% |
| Infection |
3.3% |
| Vomiting |
3.3% |
| Death |
3.0% |
| Nausea |
3.0% |
| Bronchitis |
2.7% |
| Convulsion |
2.7% |
| Dyspnoea |
2.7% |
| Infusion Site Swelling |
2.7% |
| Lung Infection |
2.7% |
| Infusion Site Infection |
2.3% |
|
| Secondary |
| Immunodeficiency Common Variable |
53.7% |
| Hypogammaglobulinaemia |
20.4% |
| Immunodeficiency |
4.4% |
| Blood Immunoglobulin G Decreased |
3.8% |
| B-cell Lymphoma |
3.5% |
| Hypoglobulinaemia |
2.5% |
| Selective Igg Subclass Deficiency |
2.4% |
| Primary Immunodeficiency Syndrome |
1.8% |
| Selective Iga Immunodeficiency |
1.5% |
| Rhinitis Allergic |
1.0% |
| Congenital Hypogammaglobulinaemia |
0.8% |
| Premedication |
0.8% |
| Back Injury |
0.6% |
| Product Used For Unknown Indication |
0.6% |
| Hypothyroidism |
0.5% |
| Humoral Immune Defect |
0.5% |
| Combined Immunodeficiency |
0.4% |
| Vitamin D Deficiency |
0.3% |
| Cystitis |
0.3% |
| Blood Immunoglobulin A |
0.3% |
|
| Respiratory Tract Infection |
12.4% |
| Sinusitis |
7.5% |
| Fatigue |
7.4% |
| Headache |
7.0% |
| Infusion Site Swelling |
6.8% |
| Upper Respiratory Tract Infection |
6.8% |
| Urinary Tract Infection |
5.9% |
| Pneumonia |
4.9% |
| Transmission Of An Infectious Agent Via A Medicinal Product |
4.7% |
| Dyspnoea |
4.3% |
| Infusion Site Erythema |
4.0% |
| Candidiasis |
3.7% |
| Infection |
3.4% |
| Meningitis Aseptic |
3.4% |
| Pyrexia |
3.3% |
| Blood Sodium Decreased |
3.1% |
| Lung Infection |
3.1% |
| Pharyngitis |
2.8% |
| Vomiting |
2.8% |
| Diarrhoea |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
52.2% |
| Immunodeficiency Common Variable |
15.7% |
| Hypogammaglobulinaemia |
6.1% |
| Premedication |
6.1% |
| Asthma |
4.3% |
| Drug Use For Unknown Indication |
3.5% |
| Adverse Event |
0.9% |
| Antiviral Prophylaxis |
0.9% |
| Anxiety |
0.9% |
| Back Pain |
0.9% |
| Blood Cholesterol Increased |
0.9% |
| Bronchitis Chronic |
0.9% |
| Depression |
0.9% |
| Gastrooesophageal Reflux Disease |
0.9% |
| Hereditary Angioedema |
0.9% |
| Histoplasmosis |
0.9% |
| Immunoglobulins Decreased |
0.9% |
| Multiple Myeloma |
0.9% |
| Multiple Sclerosis |
0.9% |
| Neutropenia |
0.9% |
|
| Product Quality Issue |
12.5% |
| Malaise |
8.3% |
| Tachycardia |
8.3% |
| Arthralgia |
4.2% |
| C-reactive Protein Increased |
4.2% |
| Contusion |
4.2% |
| Drug Ineffective |
4.2% |
| Dyskinesia Oesophageal |
4.2% |
| Haemorrhage |
4.2% |
| Headache |
4.2% |
| Immunodeficiency Common Variable |
4.2% |
| Infective Exacerbation Of Bronchiectasis |
4.2% |
| Myalgia |
4.2% |
| Oxygen Saturation Decreased |
4.2% |
| Pain |
4.2% |
| Pancreatitis |
4.2% |
| Pruritus |
4.2% |
| Pruritus Generalised |
4.2% |
| Pyelonephritis |
4.2% |
| Pyrexia |
4.2% |
|
